About Dr. Tibes
"The Tibes Lab Vision is to utilize RNAi to systematically evaluate molecular vulnerabilities in AML to advance patient care"
— Raoul Tibes, M.D., Ph.D.
I came to Arizona after my fellowship in hematology-oncology at MD Anderson Cancer Center, to advance clinical care of leukemia patients and conducting clinical studies with novel targeted cancer therapeutics. Results from my lab’s research into “novel functional targets” in leukemic cells are currently being translated by proposing clinical trials of new combination therapies in AML. This is a uniquely rewarding experience. My lab is translationally oriented and our research is intended to translate findings immediately into the clinic. As a physician and scientist I am able to carry results forward into design of clinical trials or research on biomarkers. My team in the lab is closely involved in these steps and we share a common vision of improving patient care through translational research.
- Target discovery in cancer/hematological malignancies
- Molecular targeted therapies in Cancer
- Clinical trials in hematological malignancies (Phase I-II)
- RNA interference
- Leukemias/myeloid malignancies [AML, ALL, MDS, MPN, CML]